ASLAN Pharmaceuticals

You are now leaving our web site.
I understand
Originator Outlicenced Partner
Varlitinib
  • Discovery
  • Preclinical
  • Phase 1
  • Phase 2
  • Pivotal
Array BioPharma
HYUNDAI Pharmaceuticals
ASLAN002
  • Discovery
  • Preclinical
  • Phase 1
  • Phase 2
  • Pivotal
Bristol-Myers Squibb
Bristol-Myers Squibb
ASLAN003
  • Discovery
  • Preclinical
  • Phase 1
  • Phase 2
  • Pivotal
Almirall
ASLAN004
  • Discovery
  • Preclinical
  • Phase 1
  • Phase 2
  • Pivotal
CSL
ASLAN005
  • Discovery
  • Preclinical
  • Phase 1
  • Phase 2
  • Pivotal
A*STAR
Modybodies
  • Discovery
  • Preclinical
  • Phase 1
  • Phase 2
  • Pivotal
Nanyang Technological University

Varlitinib

Pivotal

A pan-HER inhibitor in pivotal development in biliary tract, gastric and breast cancers.

Read More About Varlitinib

ASLAN002

Phase 2

RON and MET inhibitor in phase 2 development for gastric and breast cancer

Read More About ASLAN002

ASLAN003

Phase 1

A DHODH inhibitor that has the potential to be developed for inflammation and oncology

Read More About ASLAN003

ASLAN004

Preclinical

A fully human monoclonal antibody against interleukin-13 receptor α1 that inhibits signalling through IL4 and IL13

Read More About ASLAN004

ASLAN005

Preclinical

ASLAN005 is a novel monoclonal antibody targeted against the human RON (Recepteur d’Origine Nantais) receptor tyrokinase, which is both an immuno-oncology target, as well as a growth and survival factor in multiple tumour types.

Read More About ASLAN005

Modybodies

Discovery

Modybodies are novel stabilised heavy chain human monoclonal antibody (mAb) fragments that can be assembled into multi-specific formats.

Read More About Modybodies

Therapeutic Areas

We focus on Asia prevalent tumour types, including gastric cancer, biliary tract cancer and breast cancer. As few effective therapies exist to treat these diseases, there is a significant unmet need globally.

Biliary Tract Cancer Breast Cancer Gastric Cancer

Biliary Tract Cancer

Biliary Tract Cancer (BTC) consists of gall bladder cancer, cholangiocarcinoma (CCA)(both intraheptatic and extrahepatic) and cancer of the ampulla at Vater.

Globally, CCA is the second most common form of liver cancer. BTC is a heterogeneous and poorly understood diseases with very limited treatment options. Currently, there are no approved targeted therapies for the treatment of BTC. There is strong scientific rationale for HER inhibitors in BTC, demonstrating aberrant pathway activity with disease progression. [1],[2].

There is a reported higher prevalence of biliary tract cancer in Asia versus the rest of the world, with very high incidence rates reported in northeast Thailand (where CCA represents approximately 85% of total primitive liver cancers), as well as in China and Korea[3].

ASLAN is currently planning clinical trials in BTC, targeting HER pathways.

[1] Genomic and Genetic Characterization of Cholangiocarcinoma Identifies Therapeutic Targets for Tyrosine Kinase Inhibitors. Gastroenterology 2012 Apr; 142 (4): 1021-1031.e15.

[2] Kim HJ et al. Ann Oncol. 2007 May; 18(5): 892-7.

[3] Sripa B, Kaewkes S, Sithithaworn P, et al. Liver fluke induces cholangiocarcinoma. PLoS Med 2007;4:e201.

Breast Cancer

Breast cancer is the second most common cancer in the world and the most common cancer amongst women. In 2012, an estimated 1.67 million new breast cancer cases were diagnosed (25% of all cancers). In terms of mortality, breast cancer is the fifth most common cause of death from cancer (522,000 deaths)[1]. The prognosis for breast cancer is favourable when patients are diagnosed and treated early. However, there exists a large unmet medical need for metastatic breast cancer. Metastatic breast cancer refers to the stage of disease when cancer has spread beyond the breast to other organs in the body via the bloodstream or the lymphatics. A large proportion of patients with metastatic breast cancer may develop or present with resistance against existing approved HER2 therapies.

There is strong scientific rationale for the development of a small molecule inhibitor targeting multiple HER family members, and ASLAN is conducting on-going trials for ASLAN001 in metastatic breast cancer.

[1] http://globocan.iarc.fr

Gastric Cancer

Gastric Cancer (GC) is the fifth most common cancer worldwide, with 952,000 cases diagnosed in 2012[2], constituting 6.8% of total diagnoses. The current prognosis for gastric cancer is poor, with the five-year relative survival rates of patients with gastric cancer below 30% in most countries.[2] According to the World Cancer Research Foundation, the highest incidence of stomach cancer is in Asia, Latin America and Caribbean, with the rate of new cases of stomach cancer being more than four times higher in Asia compared with Africa[3].

Gastric cancer is a heterogeneous disease and the molecular pathogenesis is complex. However, current treatment of gastric cancer still insufficiently accounts for the molecular and clinical heterogeneity of the disease. Current clinical guidelines recommend use of trastuzumab combined with chemotherapy for HER2+ (amplified) patients with advanced gastric cancer. However, the majority of gastric cancer patients do not have HER2 amplified tumours and there remains a great need for novel therapies. In second-line treatment, only one agent, ramucirumab, has been approved for treatment of gastric cancer.

The scientific rationale for EGFR and other HER family inhibitors, as well as cMET inhibitors, is strong with protein over-expression demonstrated in more than 50% of gastric cancer tumours. ASLAN is currently conducting phase 2 trials for its pan-HER and cMET/RON inhibitors in the gastric cancer patient populations.

[1] http://globocan.iarc.fr

[2] Brenner H, Rothenbacher D, Arndt V. Epidemiology of stomach cancer. Methods Mol Biol. 2009; 472:467-77.